Table 1.
Patient characteristics
| Variable | Cancer (n = 221) |
High-risk (n = 18) |
Healthy control (n = 69) |
p-value |
|---|---|---|---|---|
| Age at surgery (years) | 57 (47–66) | 45 (36–51) | 38 (26–47) | < 0.0001 |
| Racea | < 0.0001 | |||
| Caucasian | 191 (86%) | 14 (78%) | 37 (54%) | |
| African American | 26 (12%) | 4 (22%) | 27 (40%) | |
| Others | 4 (2%) | 4 (6%) | ||
| TNM stagea | ||||
| 0 | 3 (1.5%) | |||
| 1 | 124 (63%) | |||
| 2 | 44 (22%) | |||
| 3 | 27 (13.5%) | |||
| Gradea | ||||
| 1 | 24 (11%) | |||
| 2 | 86 (40%) | |||
| 3 | 107 (49%) | |||
| Histology | ||||
| IDC | 164 (74%) | |||
| ILC | 27 (12%) | |||
| IDC + ILC | 12 (6%) | |||
| Others | 18 (8%) | |||
| ER+a | 164 (82%) | |||
| PR+a | 143 (72%) | |||
| HER2+a | 15 (8%) | |||
| TNBCa | 30 (15%) | |||
| LVIa | 90 (43%) | |||
| Node positivea | 109 (52%) | |||
Data are presented as number of patients (%) or median (interquartile range)
aMissing data: age (n = 1), race (n = 1), stage (n = 23), grade (n = 4), ER (n = 21), PR (n = 22), HER2 (n = 37), TNBC (n = 23), LVI (n = 14), and node-positive status (n = 10). Percentages are calculated from the total number of patients with known values
IDC, invasive ductal carcinoma; ILC, invasive lobular carcinoma; ER, estrogen receptor; PR, progesterone receptor; HER2, human epidermal growth factor 2; TNBC, triple-negative breast cancer; LVI, lymphovascular invasion